Clinical datasets have shown that BRG1 protein levels are over-expressed in prostate cancer, in the absence of consistent significant deleterious genetic mutations evident in SMARCA4 [42, 44–46]. The gene discussed is SMARCA4; the disease is prostate carcinoma.